News and Announcements
SUDA’s Annual Report to Shareholders
- Published October 02, 2015 2:17PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
30th September 2015, ASX Announcement
Like most listed entities the Board of SUDA is focused on “creating sustainable value for shareholders”. Your Board has spent considerable time ensuring management has a very clear understanding of the building blocked required to “create sustainable value”.
Our key building blocks are designed to:
- Build a global reputation for innovation and excellence in oro-mucosal drug delivery;
- Execute licence deals and trade sales to generate upfront, milestone and royalty payments;
- Create strategic alliances and partnerships through scientific collaboration;
- Expand our patent portfolio and product pipeline;
- Build investor community awareness and manage expectations;
- Comply with best practice corporate governance and financial management; and
- Build flexible and responsive management.
Under each of these building blocks the management team has specific work plans and budgets and is accountable to the CEO, and in turn, to the Board.
To view the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
